In HBV+ DLBCL, systemic immune alterations provide further support for this paradigm: a lower absolute lymphocyte count (ALC) in peripheral blood predicts poor chemotherapy response,36, 37, 38 and peripheral CD4+ T cell levels decline markedly during chemotherapy in HBV‐related DLBCL patients.39 The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.